The Proteomic Profile of Keratinocytes and Lymphocytes in Psoriatic Patients.
4-HNE-protein adducts
keratinocytes
lymphocytes
proteome
psoriasis
Journal
Proteomics. Clinical applications
ISSN: 1862-8354
Titre abrégé: Proteomics Clin Appl
Pays: Germany
ID NLM: 101298608
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
10
07
2018
revised:
04
12
2018
pubmed:
17
1
2019
medline:
25
1
2020
entrez:
17
1
2019
Statut:
ppublish
Résumé
Psoriatic skin lesions are associated with chronic inflammation related to immune cell activity. Therefore, the aim of this study is to compare changes in the proteome of psoriatic keratinocytes and lymphocytes. A proteomics approach is used to analyze the expression of proteins in keratinocytes and lymphocytes from psoriatic patients and healthy controls. As a result 2119 proteins for keratinocytes and 1235 proteins for lymphocytes are identified. Psoriatic keratinocytes has 68 downregulated and 7 upregulated proteins and psoriatic lymphocytes has 106 downregulated and 67 upregulated proteins compared to healthy individuals. The list of downregulated proteins includes proteins involved in antioxidant homeostasis and, transcription regulation; upregulated proteins are involved in glycolytic processes and translation. These changes are accompanied by an increased level of 4-Hydroxynonenal-protein adducts; control cells are characterized by 4-Hydroxynonenal-Lysine adducts formed with structural and binding proteins, while in psoriatic cells 4-Hydroxynonenal-Lysine, 4-Hydroxynonenal-Histidine, and 4-Hydroxynonenal-Cysteine adducts with various molecular function proteins occur. This study highlights the changes in psoriatic keratinocytes and lymphocytes that can be directly involved in the development of psoriasis. In both cell types the most significant changes are associated with upregulation of phosphoglycerate mutase 1 and downregulation of thioredoxin reductase.
Identifiants
pubmed: 30648813
doi: 10.1002/prca.201800119
doi:
Substances chimiques
Proteome
0
Thioredoxin-Disulfide Reductase
EC 1.8.1.9
Phosphoglycerate Mutase
EC 5.4.2.11
phosphoglycerate mutase 1, human
EC 5.4.2.11
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1800119Informations de copyright
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.